Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | -2.13% | 199.08 | 1.3% | $749.78m | |
| GILD | Gilead Sciences, Inc. | -2.66% | 62.51 | 0.9% | $372.82m | |
| CELG | Celgene Corporation | -1.80% | 93.99 | 1.3% | $323.19m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -6.61% | 115.33 | 2.0% | $295.67m | |
| ILMN | Illumina, Inc. | -3.17% | 279.44 | 3.5% | $272.03m | |
| BIIB | Biogen Inc. | -2.68% | 225.85 | 1.3% | $258.17m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -2.20% | 180.18 | 1.9% | $251.48m | |
| EXAS | Exact Sciences Corporation | -0.77% | 116.96 | 24.1% | $238.08m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -2.77% | 286.85 | 2.6% | $193.57m | |
| A | Agilent Technologies, Inc. | -3.01% | 69.58 | 1.6% | $188.95m | |
| SRPT | Sarepta Therapeutics, Inc. | -1.54% | 93.61 | 14.7% | $184.96m | |
| BMRN | BioMarin Pharmaceutical Inc. | -2.12% | 75.76 | 4.3% | $97.12m | |
| INCY | Incyte Corporation | -4.27% | 81.91 | 2.5% | $90.56m | |
| GHDX | Genomic Health, Inc. | -0.35% | 73.26 | 1.8% | $81.69m | |
| NBIX | Neurocrine Biosciences, Inc. | 0.36% | 97.59 | 5.0% | $71.75m |
Company Profile
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.